{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:56:30Z","timestamp":1791251790454,"version":"4.1.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.2515\/therapie\/2013020","type":"journal-article","created":{"date-parts":[[2013,6,17]],"date-time":"2013-06-17T12:59:05Z","timestamp":1371473945000},"page":"107-111","source":"Crossref","is-referenced-by-count":12,"title":["New Formulation of Methadone for Opioid Dependence in France: Acceptability and Diversion\/Misuse Liability"],"prefix":"10.1016","volume":"68","author":[{"given":"C\u00e9line","family":"Eiden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"L\u00e9glise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Bertomeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivianne","family":"Clavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Faillie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Peyri\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.2515\/therapie\/2013020_bb0875","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/j.1526-4637.2010.00877.x","article-title":"Post-marketing surveillance of methadone and buprenorphine in the United States","volume":"11","author":"Dasgupta","year":"2010","journal-title":"Pain Med"},{"key":"10.2515\/therapie\/2013020_bb0880","series-title":"Strat\u00e9gies th\u00e9rapeutiques pour les personnes d\u00e9pendantes des opiac\u00e9s : place des traitements de substitution","year":"2004"},{"key":"10.2515\/therapie\/2013020_bb0885","unstructured":"Commission de la transparence. Recommendations HAS (2007). Methadone (chlorydrate de) g\u00e9lules. http:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/ct-5198_methadone.pdf"},{"key":"10.2515\/therapie\/2013020_bb0890","unstructured":"Circulaire DGS\/DHOS n\u00b02002-57 du 30 janvier 2002 relative \u00e0 la prescription de la m\u00e9thadone par les m\u00e9decins exer\u00e7ant en \u00e9tablissement de sant\u00e9, dans le cadre de l\u2019initialisation d\u2019un traitement de substitution pour les toxicomanes d\u00e9pendants majeurs aux opiac\u00e9es. http:\/\/www.sante.gouv.fr\/fichiers\/bo\/2002\/02-08\/a0080670.htm"},{"key":"10.2515\/therapie\/2013020_bb0895","first-page":"4","article-title":"Analyse de la r\u00e9partition par d\u00e9partements des patients recevant un traitement par BHD (Subutex\u00ae et ses g\u00e9n\u00e9riques) et par m\u00e9thadone en 2011","volume":"46","author":"Wilquin","year":"2012","journal-title":"Le Flyer"},{"key":"10.2515\/therapie\/2013020_bb0900","unstructured":"R\u00e9sultats de l\u2019enqu\u00eate Oppidum ANSM 2009. http:\/\/www.ansm.sante.fr\/var\/ansm_site\/storage\/original\/application\/83d45de068482ab831466a00a97e4962.pdf"},{"key":"10.2515\/therapie\/2013020_bb0905","unstructured":"Plan de gestion des risques ANSM 2008. http:\/\/ansm.sante.fr\/Activites\/Surveillance-des-stupefiants-et-des-psychotropes\/Medicaments-a-risque-d-usage-detourne-ou-de-dependance\/Medicaments-a-risque-d-usage-detourne-ou-de-dependance\/METHADONE-AP-HP-sirop-et-gelules\/(language)\/fre-FR"},{"key":"10.2515\/therapie\/2013020_bb0910","unstructured":"Suivi post AMM ANSM 2011. Bilan du suivi national de la methadone (sirop et g\u00e9lule) apr\u00e8s 3 ans de commercialisation de la methadone gelule. Commission nationale des stup\u00e9fiants et psychotropes. http:\/\/ansm.sante.fr\/content\/download\/39461\/516109\/version\/1\/file\/commission-srup-compte-rendu-201011.pdf"},{"key":"10.2515\/therapie\/2013020_bb0915","first-page":"4","article-title":"\u00c9tude observationelle de l\u2019\u00e9quivalence th\u00e9rapeutique des formes sirop et g\u00e9lules de m\u00e9thadone \u00ab Analyse interm\u00e9diaire des 101 premiers patients \u00bb","volume":"39","author":"Maire","year":"2010","journal-title":"Le Flyer"},{"key":"10.2515\/therapie\/2013020_bb0920","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.drugalcdep.2006.01.016","article-title":"Development of opioid formulations with limited diversion and abuse potential","volume":"83S","author":"Fudala","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"10.2515\/therapie\/2013020_bb0925","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.drugalcdep.2006.01.006","article-title":"History and current perspectives on the use of drug formulations to decrease the abuse of prescription drugs","volume":"83S","author":"Schuster","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"10.2515\/therapie\/2013020_bb0930","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1472-8206.2011.00950.x","article-title":"Which psychoactive prescription drugs are illegally obtained and through which ways of acquisition? About OPPIDUM survey","volume":"4","author":"Frauger","year":"2012","journal-title":"Fundam Clin Pharmacol"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716309064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716309064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T11:43:37Z","timestamp":1554291817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716309064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0040595716309064"],"URL":"https:\/\/doi.org\/10.2515\/therapie\/2013020","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}